Sandoz gains backing for Enbrel patent term review
Sandoz, a subsidiary of Swiss pharmaceutical company Novartis, has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of biologic Enbrel (etanercept) until 2029.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.
